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The review summarizes recent epidemiological studies that examined the relationship between osteoporosis
and sarcopenia to assess the impact of vitamin D status or supplementation on health outcomes related to
these two medical conditions.
Recent findings
Osteoporosis and sarcopenia are major public health problems, but whether these two diseases should be
considered alone or combined into a single condition is not clear. No consensual definition of
osteosarcopenia is largely accepted. Most observational studies demonstrate some relationship between
muscle and bone health. Vitamin D status is generally lower in study participants with bone or muscle wasting.
Studies on the effects of vitamin D supplementation on muscle or bone health have provided conflicting results,
likely because of the heterogeneity between studies. However, the most positive results were observed in study
participants with low vitamin D status and in studies that avoided massive boluses of vitamin D.
Summary
More observational and interventional studies are needed to confirm the exact role of vitamin D in the
pathophysiology and treatment of osteosarcopenia.
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Aging is accompanied by changes in body composi-
tion, such as a decrease in bone and muscle mass.
Loss of bone and muscle with advancing age is a
huge threat to independence in later life [1]. The two
main diseases related to bone and muscle wasting
are osteoporosis and sarcopenia, respectively. These
diseases occur in relatively similar populations, and
growing evidence from preclinical and clinical re-
search supports a link between the conditions. This
association has led to the concept of the bone–
muscle unit. The key musculoskeletal pathways in-
volved in the regulation of the bone–muscle unit
were reviewed recently and were mainly focused on
biomechanical loading, endocrine pathways, and
activating receptor signalling [2
&&
]. Other recent




Vitamin D is a fat-soluble vitamin that plays a
most important role in calcium and bone metabo-
lism. Vitamin D metabolism is coordinated by the
skin, the liver, and the kidney. Vitamin D is activat-
ed into 25-hydroxyvitamin D [25(OH)D] in the liverthe active form of vitaminD, in the kidney. Changes
in calcium absorption associated with vitamin D
deficiency affect muscle and bone mass [5]. The
age-related decline in vitamin D receptor expression
and 1,25(OH)D activity affects proinflammatory
cytokines in the skeletal muscle, and vitamin D
deficiency enhances bone marrow adipogenesis
and intramuscular adipose tissue, which reduces
functionality in skeletal tissues [6]. In the muscle
tissue, a regulatory effect of vitamin D on calciumVolume 20  Number 6  November 2017
KEY POINTS
 Observational studies show some relationship between
bone and muscle status.
 Numerous in-vitro and in-vivo studies demonstrated that
vitamin D plays an important role in bone and
muscle metabolism.
 No interventional studies have been performed to
assess the effect of vitamin D in an
osteosarcopenic population.
 In study participants who are at a high risk of falls, as
all osteosarcopenic patients could be considered, a
dose of 800–2000 IU of vitamin D/day should be
given to reach the recommended minimal serum
25(OH)D level of 75nmol/l.
 More well designed randomized controlled trials in
specific osteosarcopenic populations are needed to
assess the effectiveness of vitamin D supplementation
on the prevention and management of this
medical condition.
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controlling protein anabolism has been reported [6].
The current review discusses and critically
reviews the most recent epidemiological studies of
osteosarcopenia and the potential impact of vitamin
D on its pathogenesis andmanagement. We include
observational (i.e. cohort or case–control) and inter-
ventional (i.e. randomized and controlled) studies.OSTEOPOROSIS, SARCOPENIA, OR
OSTEOSARCOPENIA?
Osteoporosis and sarcopenia aremajor public health
problems [7–9,10
&
]. Osteoporosis is defined as a
systemic skeletal disease that is characterized by
low bone mass and microarchitectural deterioration
of bone tissue with a consequent increase in bone
fragility and susceptibility to fracture. Osteoporotic
fractures are a major cause of morbidity. These
injuries are associated with increased mortality
and generate costs in excess of 37 billion Euros for
patient management in Europe [11]. Sarcopenia
is operationally defined as the loss of muscle mass
and muscle function, and a recent meta-analysis-
associated sarcopenia with a higher rate of mortality
[pooled odds ratio (OR) of 3.596 (95% (confidence
interval) CI 2.96–4.37)] and functional decline
[pooled OR of six studies 3.03 (95% CI 1.80–
5.12)] [12]. A higher rate of falls and a higher inci-
dence of hospitalizations were also noted. Recent
simulations estimated that the number of individu-
als with sarcopenia will rise from 19740527 in 20161363-1950 Copyright  2017 The Author(s). Published by Wolters Kluweto 32338990 in 2045 (a 63.8% increase), which
corresponds to the overall prevalence rates in the
elderly of 20.2 and 22.3% for 2016 and 2045, respec-
tively [13]. The impact of both diseases on quality of
life is substantial [14,15].
Whether osteoporosis and sarcopenia should be
considered alone or combined into a single condi-
tion is not clear. Combining the loss of bone mass
and muscle strength into a single diagnosis called
‘sarcoosteopenia’ was previously suggested based on
the abundant literature documenting the positive
relationship of muscle and bone mass, which is
partially because of muscle-induced skeletal strain
[16]. Other terms, such as sarcoosteoporosis or
osteosarcopenia, have also been suggested, but no
consensus has been reached. Anyway, the opera-
tional definition of the combination of osteoporosis
and sarcopenia is not clear, which resulted in het-
erogeneity in all epidemiological-related studies.RELATIONSHIP BETWEEN OSTEOPOROSIS
AND SARCOPENIA
Muscle–bone interactions have been exhaustively
investigated in preclinical and clinical studies over
the last decade. However, recent data are of particu-
lar interest to better understand the relationship
between bone and muscle health. Some of these
studies characterized the phenotype of osteosarco-
penic patients [17,18]. The first study examined
a cohort of 680 study participants from Australia
and demonstrated that osteosarcopenic patients
(defined as low bone mineral density, low muscle
strength, and low muscle mass) were older and
mostly women, were at a high risk for depression
and malnutrition, had a BMI lower than 25, and
exhibited a higher prevalence of peptic disease,
inflammatory arthritis, maternal hip fracture, histo-
ry of atraumatic fracture, and impaired mobility
[17]. The second study was a small cross-sectional
study of 68 prefrail German adults that reported that
osteosarcopenic participants (defined as low bone
mineral density and low muscle mass) exhibited
significantly reduced hand grip strength, increased
chair rising and sit-to-stand power times, and sig-
nificantly increased bone turnover markers [18].
Other studies assessed the interconnection be-
tween muscle and bone wasting in cross-sectional
studies. The skeletal muscle mass index in 216 Japa-
nese women with recent vertebral fracture was low-
er, and the prevalence of sarcopenia was higher than
that of 1608 controls, even after adjusting for age,
which suggests that sarcopenia is a risk factor for
vertebral fractures [19]. Another study of 17891
study participants of African-American, Whites,
and Chinese ethnicities demonstrated that studyr Health, Inc. www.co-clinicalnutrition.com 499
Micronutrientsparticipants with sarcopenia (defined by a low mus-
cle mass) were two times more likely to have osteo-
penia/osteoporosis compared with normal study
participants (OR¼2.04; 95% CI¼1.61, 2.60) [20].
Similarly, study participants with sarcopenia (low
muscle mass and low grip strength) were approxi-
mately two times more likely to exhibit osteopenia/
osteoporosis than were normal study participants
(OR¼1.87; 95% CI¼1.09, 3.20). These results were
consistent with the preliminary data from the Sar-
coPhAge study, which demonstrated more osteopo-
rotic (based on bone mineral density assessment)
women among sarcopenic study participants (based
on muscle mass and muscle strength or physical
function) than among nonsarcopenic study partic-
ipants [21]. A significantly lower appendicular
lean mass index was also observed in osteoporotic
women compared with nonosteoporotic women
(P¼0.025). Lower muscle strength was also noted
in osteoporotic study participants (P¼0.023).
Few perspective studies have been published
recently. One study followed a cohort of 750women
aged 50–94 years for one decade [22
&
]. By the end of
follow-up, there were 190 deaths. After controlling
for potential confounding variables, low bone min-
eral density was significantly associated with a
higher risk of mortality, and the low appendicular
lean mass had borderline significance. Another
study that followed 1099 study participants aged
over 60 years found that osteoporosis (based on
bone mineral density value) was a significant pre-
dictive factor for sarcopenia occurrence (defined
as low muscle mass and low muscle strength or
low physical performance) in the next 4 years
[23
&&
]. The associated risk, expressed as the OR,
was 2.99 (95% CI 1.46–6.12; P¼0.003).
These recent results confirm an interaction
between muscle and bone. However, caution must
be kept in mind when interpreting these results
because the definitions of muscle or bone wasting
were highly heterogeneous between studies and the
design of some studies did not capture the causality
of the relationship.POTENTIAL EFFECT OF VITAMIN D ON
BONE AND MUSCLE HEALTH
There are many reasons to consider how vitamin D
may have a potential beneficial effect onmuscle and
bone, as recently reviewed by various experts and
scientific societies [6,24–28]. To the best of our
knowledge, very few studies were designed to assess
vitamin D status or the effects of vitamin D supple-
mentation in osteosarcopenic patients. However,
the interaction between muscle and bone led to
the hypothesis that an improvement in one organ500 www.co-clinicalnutrition.commay be beneficial to the other. Therefore, it is
important to review the most recent studies of the
relationship between vitamin D and muscle or bone
health.
Observational studies consistently demonstrate
a lower level of 25(OH)D, which is the metabolite
measured for evaluating the vitamin D status of an
individual [29], in osteoporotic patients (defined by
low bone mineral density or the presence of frac-
ture) compared with nonosteoporotic study partic-
ipants. Far fewer studies are available in sarcopenic
study participants. However, three recent studies are
of particular interest for muscle and bone issues.
The first study was performed on US women over
65 years of age residing in long-term care and dem-
onstrated that initially deficient women defined as
25(OH)D less than 50nmol/l exhibited a greater
decline in physical function at 12 and 24 months,
a larger increase in cognitive deficits at 12 months
and more falls compared with women sufficient in
vitamin D at baseline, despite daily supplementa-
tion of 800 IU of vitamin D in all participants [30].
The second study investigated the relationship of
serum 25(OH)D levels with physical activity and
muscle fatigue in 85 healthy older adults aged
65 years or over [31]. The results demonstrated that
the 25(OH)D levels were significantly and indepen-
dently associated with self-reported muscle fatigue
scores and some biomarkers considered by the
authors as markers of muscle fatigue (e.g. troponin
I and lactate dehydrogenase). The last study assessed
the association between vitamin D status and the
incidence of sarcopenia in 1705 men aged 70 years
and over [32
&&
]. Men with 25(OH)D levels in the
lowest quartiles (<40nmol/l) exhibited significant
associations with an increased odds of incident
sarcopenia compared with men having 25(OH)D
levels in the highest quartiles (>68.9nmol/l) over
5 years with an OR of 2.53 (95% CI 1.14, 5.64) in an
adjusted analysis. The results of these recent obser-
vational studies confirm the potential interaction
between vitamin D and muscle and bone health.
The effects of vitamin D supplementation on
fractures, falls, andmuscle function were investigat-
ed in a large number of randomized controlled trials.
Various meta-analyses summarized the effects ob-
served in these trials. Thesemeta-analyses show that
vitamin D should be added to calcium supplemen-
tation to significantly reduce the incidence of frac-
ture [33–35]. Even if the heterogeneity in doses of
the vitamin D and calcium is high, it is generally
accepted that at least 800 IU/day should be added to
a minimum of 500mg/day of calcium supplemen-
tation to have an effect on fractures. The results are
globally similar for the effect on falls, but recent
studies have clearly shown that very large doses ofVolume 20  Number 6  November 2017
Vitamin D and osteosarcopenia: an update Bruye`re et al.vitamin D (i.e. 300000 or 500000 IU) significantly
increased the number of falls, thus making the
interpretation of meta-analyses including these
trials quite convoluted [36
&
,37]. The two recent
meta-analyses that assessed the effect of vitamin
D supplementation on muscle strength provided
conflicting results [38,39]. One meta-analysis
focused on community-dwelling older persons
and included 15 studies that demonstrated no
improvement in muscle strength after the adminis-
tration of vitaminDwith orwithout calcium supple-
ments [38]. The other study included 30 randomized
controlled trials of 5615 individuals (no age restric-
tion was included in this meta-analysis) and showed
that vitamin D supplementation had a small posi-
tive impact on muscle strength but no effect
on muscle mass or muscle power [39]. This meta-
analysis was of particular interest because the sensi-
tivity analyses showed, in sensitivity analyses,
that supplementation of people who presented
a 25(OH)D level less than 30nmol/l resulted in
a significantly greater improvement in muscle
strength compared with people who presented a
25(OH)D level at least 30nmol/l (P¼0.02). Higher
effects were also found for people who demonstrat-
ed an increased 25(OH)D concentration of at least
25nmol/l within the study duration. However,
it should be pointed out that in these two meta-
analyses, a huge heterogeneity was observed regard-
ing vitamin D metabolites, doses, and mode of
administration. Consequently, more well designed
experimental studies are needed to confirm the
exact place of vitamin D supplementation in the
management of concomitant bone and muscle
disorders.
More recent studies, which were not included
in these meta-analyses, provided some interesting
information. The first study in 130 sedentary men
aged 65–90 years with 25(OH)D levels less than
75nmol/l and Short Physical Performance Battery
test (SPPB) scores of 9 or less showed that daily
vitamin D (4000 IU) for 9 months did not improve
the SPPB scores or gait speed [40
&
]. However, the
SPPB is only a surrogate marker of muscle function,
and it lacks sensitivity for measuring clinical change
making the interpretation of the results more con-
voluted. Another study demonstrated that daily
800 IU and twice weekly 20000 IU of vitamin D
had no effect on muscular strength, balance, or
quality of life in 297 postmenopausal women with
osteopenia or osteoporosis compared with daily
800 IU alone [41
&
]. However, it should be pointed
that most of the participants in this study exhibited
adequate vitamin D status (i.e. over 50nmol/l), and
30% exhibited baseline levels more than 75nmol/l,
which supports the results of previousmeta-analyses1363-1950 Copyright  2017 The Author(s). Published by Wolters Kluwethat found no effect of vitamin D in study partic-
ipants with vitamin D status over 30nmol/l. Post
hoc analyses of the PROVIDE study have showed
results of particular interest [42
&
]. The PROVIDE
study randomized sarcopenic older adults to a vita-
min D and leucine-enriched whey protein supple-
ment (20g whey protein, 3 g total leucine, 9 g
carbohydrates, 3 g fat, 800 IU vitamin D, and a mix-
ture of vitamins, minerals, and fibres, twice a day) or
isocaloric control and showed that studyparticipants
who received the vitamin D and leucine-enriched
whey protein medical nutrition drink gained more
appendicular muscle mass and improved lower
extremity function, as assessed using the chair stand
test, compared with controls. The post hoc study
demonstrated that participants with higher baseline
25(OH)D concentrations (>50nmol/l) and dietary
protein intake (>1.0g/kg/day) had, independently
of other determinants, greater gains in appendicular
muscle mass, skeletal muscle index, and relative ap-
pendicularmusclemass in response to thenutritional
intervention. The authors hypothesized that vitamin
Dcouldact synergisticallywith leucine and insulin to
stimulate muscle protein synthesis, likely through
sensitizing the anabolic pathways induced by insulin
and leucine. They concluded that the current cutoffs
in the recommendations for vitamin D (50nmol/l)
and protein intake (1.0–1.2g/kg/day) should be con-
sidered the ‘minimum’ for adults with sarcopenia to
respond adequately to nutritional strategies aimed at
attenuating muscle loss.
Given the heterogeneity in the design of obser-
vational and interventional studies, there are still
some controversies about the exact role of vitaminD
supplementation in musculoskeletal health. How-
ever, experts generally agree that a minimum level
of 50nmol/l of 25(OH)D must be reached in the
general elderly population and that 75nmol/l
should be the target in fragile study participants
who are at elevated risk for falls and fractures
[24,43]. A dose of 800–2000 IU of vitamin D/day
should be given, under the supervision of a physi-
cian, to reach this last target.CONCLUSION
More studies confirmed the interconnection be-
tween bone and muscle, which reemphasizes the
importance of the bone–muscle unit. However,
huge heterogeneity, primarily in the definition of
muscle or bone disorders in the various published
epidemiological studies, complicates the interpreta-
tion and clinical implications of these studies. Vita-
min D plays a role in muscle and bone metabolism,
and it has been widely investigated in observational
and interventional studies. The conflicting results ofr Health, Inc. www.co-clinicalnutrition.com 501
Micronutrientsthese studies are primarily the result of the huge
heterogeneity in study design. However, interven-
tional studies performed using more physiological
doses of vitamin D (i.e. avoiding very large, non-
physiological doses) or in study participants with
low vitamin D status have provided more beneficial
effects on muscle and bone health compared with
studies that included more study participants with
optimal vitamin D status.Acknowledgements
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